Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients
暂无分享,去创建一个
P. Vitulo | G. Panarello | M. Bulati | P. Conaldi | A. Mularoni | M. Miele | F. Timoneri | M. D. Di Bella | M. C. Sorrentino | G. Russelli | R. Busà
[1] D. Schwartz,et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus , 2021, American Journal of Transplantation.
[2] S. Adamopoulos,et al. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients , 2021, American Journal of Transplantation.
[3] M. Ison,et al. The future of SARS-CoV-2 vaccines in transplant recipients: To be determined , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[4] D. Segev,et al. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. , 2021, JAMA.
[5] M. Ison,et al. Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.